On 7 August 2024, Novo Nordisk released its financial report which showed a strong increase in profits in the first half of 2024. Novo Nordisk’s total sales equalled DKK 133.4 billion in the first six months of 2024, an increase of 24% in DKK and 25% when measured according to constant exchange rates (CER).
Diabetes and Obesity care sales saw an increase of 27% (CER) to DKK 125 billion (US$18.3bn), primarily driven by GLP-1 diabetes sales growth of 32% (CER) and Obesity care, including products such as Ozempic, growing by 37% (CER). Novo Nordisk reports that it continues to be the global market leader in the GLP-1 segment for diabetes care with 56% value market share.
Highlights for the first 6 months of 2024 are reported to include the approval of Awiqli® (insulin icodec) in the EU (March 2024), Japan and China (June 2024) and a label extension for Wegovy® (semaglutide) in the EU (July 2024).
The second half of 2024 is expected to see a further 22-28% (CER) growth in sales and operating profit is expected to grow by as much as 20-28% (CER).